Antidiabetic Drugs in the Treatment of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The public health burden of type 2 diabetes mellitus and Alzheimer’s disease is steadily increasing worldwide, especially in the population of older adults. Epidemiological and clinical studies suggest a possible shared pathophysiology between the two diseases and an increased risk of AD in patients with type 2 diabetes mellitus. Therefore, in recent years, there has been a substantial interest in identifying the mechanisms of action of antidiabetic drugs and their potential use in Alzheimer’s disease. Human studies in patients with mild cognitive impairment and Alzheimer’s disease have shown that administration of some antidiabetic medications, such as intranasal insulin, metformin, incretins, and thiazolidinediones, can improve cognition and memory. This review aims to examine the latest evidence on antidiabetic medications as a potential candidate for the treatment of Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“In 2019, approximately 463 million individuals were affected by DM [6].”
BackgroundThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 2×
“APOE4 is the strongest genetic risk factor for AD [3], and about 25% of the population carries at least one ε4 allele [5].”
BackgroundTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“It was proposed that AD might be a metabolic disease of the brain, driven by insulin resistance and insulin-like growth factor (IGF-1) resistance [19,20].”
BackgroundBrain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
Biessels, G. J., & Despa, F. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0048-7 · Cited by 1,454
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 1×
“T2DM has also been associated with an increased risk of dementia [8,9], in particular, AD by 45–90% [10,11].”
BackgroundCraft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · cited 1×
“Therefore, AD could be considered a metabolic disease caused by insulin and IGF-1 resistance in the brain, so the term type 3 DM was proposed [18].”
BackgroundThe many faces of insulin-like peptide signalling in the brain
Fernandez, A. M., & Torres-Alemán, I. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3209 · Cited by 872 · cited 1×
“Insulin resistance and hyperglycemia as features of T2DM have a detrimental effect on cognitive abilities [15], since insulin and insulin-like growth factor, also called somatomedin C (IGF-1), play an important role in cognitive ability, neural function, and development [16].”
BackgroundRivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 1×
“It was proposed that AD might be a metabolic disease of the brain, driven by insulin resistance and insulin-like growth factor (IGF-1) resistance [19,20].”
BackgroundHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 2×
“due to its safe action profile (Figure 6) [62].”
BackgroundRelation of diabetes to mild cognitive impairment
Luchsinger, J. A., Reitz, C., Patel, B., Tang, M.-X., Manly, J. J., & Mayeux, R. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.570 · Cited by 592
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Wang, J., Gallagher, D., DeVito, L. M., Cancino, G. I., Tsui, D., He, L., Keller, G. M., Frankland, P. W., Kaplan, D. R., & Miller, F. D. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.03.016 · Cited by 474
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335 · cited 3×
“In a more recent study [60] in which researchers compared NPH insulin to insulin detemir and placebo in adults with MCI or AD, NPH insulin appeared to improve memory after 2 and 4 months compared to the placebo, while no significant effects of long-acting insulin were observed compared to the placebo.”
BackgroundResultInfluentialLong-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes
Ng, T. P., Feng, L., Yap, K. B., Lee, T. S., Tan, C. H., & Winblad, B. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131901 · Cited by 334
Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052687 · Cited by 330 · cited 1×
“Recent research shows that AD shares many common links with diseases related to insulin resistance, such as neuroinflammation, insulin signaling disorder, oxidative stress, advanced glycosylation end products (AGEs), mitochondrial dysfunction, and metabolic syndrome [17].”
BackgroundSelf-citationEnhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose
Craft, S., Asthana, S., Newcomer, J. W., Wilkinson, C. W., Matos, I. T., Baker, L. D., Cherrier, M., Lofgreen, C., Latendresse, S., Petrova, A., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1135 · Cited by 312
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285 · cited 1×
“, 2016 [43] Metformin MCI Significant improvement in verbal memory.”
BackgroundGeldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221 · cited 1×
“Although treatment with pioglitazone was tolerable, the findings did not support its efficacy in these patients [88].”
ResultClaxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations
Shinohara, M., Kanekiyo, T., Yang, L., Linthicum, D., Shinohara, M., Fu, Y., Price, L., Frisch‐Daiello, J. L., Han, X., Fryer, J. D., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24628 · Cited by 111
The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019) · Neuronal Signaling · doi:10.1042/ns20180203 · Cited by 94 · cited 2×
“APOE4 is the strongest genetic risk factor for AD [3], and about 25% of the population carries at least one ε4 allele [5].”
BackgroundAbbatecola, A. M., Lattanzio, F., Molinari, A. M., Cioffi, M., Mansi, L., Rambaldi, P., DiCioccio, L., Cacciapuoti, F., Canonico, R., & Paolisso, G. (2010) · Diabetes Care · doi:10.2337/dc09-2030 · Cited by 93
Calsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93 · cited 1×
“GLP-1 and its receptors are not found exclusively in the pancreas and vascular endothelium but are also expressed in the brain and specifically in the hippocampus, hypothalamus, cerebral cortex, and olfactory bulbs [67].”
Background
Cited by
Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14313 · Cited by 180
Yan, C., Grabowska, M. E., Dickson, A. L., Li, B., Wen, Z., Roden, D. M., Michael Stein, C., Embí, P. J., Peterson, J. F., Feng, Q., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01038-3 · Cited by 73
Tirzepatide prevents neurodegeneration through multiple molecular pathways
Fontanella, R. A., Ghosh, P., Pesapane, A., Taktaz, F., Puocci, A., Franzese, M., Feliciano, M. F., Tortorella, G., Scisciola, L., Sommella, E., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04927-z · Cited by 67
“Several studies were performed to evaluate the effects of several antidiabetic drugs like incretins, thiazolidines, metformin, and intranasal insulin in the treatment of AD [9].”
Background
Metadata
- Authors
- Michailidis, M., Tata, D. A., Moraitou, D., Kavvadas, D., Karachrysafi, S., Papamitsou, T., Vareltzis, P., & Papaliagkas, V.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-22
- Volume
- 23
- Issue
- 9
- Pages
- 4641
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4224248806
- Cited by
- 69
- References
- 34
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.